Immunai Company
Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
Investors
Technology:
Artificial Intelligence, Biotechnology, Machine Learning, Therapeutics
Industry:
AI, Data Processing, End-to-end drug development, United States
Headquarters:
New York, New York, United States
Founded Date:
2018-12-01
Employees Number:
101-250
Funding Status:
Early Stage Venture
Acquisitions Number:
2
Investors Number:
13
Total Funding:
295000000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2021-10-27
Last Funding Type:
Series B
Register and Claim Ownership